NEUROCRINE BIOSCIENCES INC Investing Cash Flow
NEUROCRINE BIOSCIENCES INC (NBIX) reported Investing Cash Flow of -$641.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$135.40M.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$506.20M, a 3664.79% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$52.90M.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$196.70M, a 896.36% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities for fiscal 2025 was -$264.40M.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities for fiscal 2024 was -$126.80M.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities for fiscal 2023 was -$467.10M.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities for fiscal 2022 was -$177.10M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$135.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$641.60M 10-Q · filed 2026-07-31 | -$694.50M derived: sum of 3 quarters · filed 2026-07-31 | -$891.20M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | -$506.20M 10-Q · filed 2026-05-05 | -$559.10M derived: sum of 2 quarters · filed 2026-05-05 | -$755.80M derived: sum of 3 quarters · filed 2026-05-05 | -$784.80M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | -$52.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$249.60M derived: sum of 2 quarters · filed 2026-02-11 | -$278.60M derived: sum of 3 quarters · filed 2026-07-31 | -$264.40M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | -$196.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$225.70M derived: sum of 2 quarters · filed 2026-07-31 | -$211.50M 10-Q · filed 2025-10-28 | -$279.80M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | -$29.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$14.80M 10-Q · filed 2026-07-31 | -$83.10M derived: sum of 3 quarters · filed 2026-07-31 | -$58.40M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $14.20M 10-Q · filed 2026-05-05 | -$54.10M derived: sum of 2 quarters · filed 2026-05-05 | -$29.40M derived: sum of 3 quarters · filed 2026-05-05 | -$57.60M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$68.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$43.60M derived: sum of 2 quarters · filed 2026-02-11 | -$71.80M derived: sum of 3 quarters · filed 2026-02-11 | -$126.80M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $24.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$3.50M derived: sum of 2 quarters · filed 2025-10-28 | -$58.50M 10-Q · filed 2025-10-28 | -$260.30M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | -$28.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$83.20M 10-Q · filed 2025-07-30 | -$285.00M derived: sum of 3 quarters · filed 2026-02-11 | -$382.30M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | -$55.00M 10-Q · filed 2025-05-05 | -$256.80M derived: sum of 2 quarters · filed 2026-02-11 | -$354.10M derived: sum of 3 quarters · filed 2026-02-11 | -$480.00M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | -$201.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$299.10M derived: sum of 2 quarters · filed 2026-02-11 | -$425.00M derived: sum of 3 quarters · filed 2026-02-11 | -$467.10M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | -$97.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$223.20M derived: sum of 2 quarters · filed 2024-10-30 | -$265.30M 10-Q · filed 2024-10-30 | -$380.90M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-06-30 | -$125.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$168.00M 10-Q · filed 2024-08-01 | -$283.60M derived: sum of 3 quarters · filed 2025-02-10 | -$344.90M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-03-31 | -$42.10M 10-Q · filed 2024-05-01 | -$157.70M derived: sum of 2 quarters · filed 2025-02-10 | -$219.00M derived: sum of 3 quarters · filed 2025-02-10 | -$187.60M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2022-12-31 | -$115.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | -$176.90M derived: sum of 2 quarters · filed 2025-02-10 | -$145.50M derived: sum of 3 quarters · filed 2025-02-10 | -$177.10M 10-K · filed 2025-02-10 | ||||
| 2022-09-30 | -$61.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | -$29.90M derived: sum of 2 quarters · filed 2023-10-31 | -$61.50M 10-Q · filed 2023-10-31 | -$37.80M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-06-30 | $31.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$200.00K 10-Q · filed 2023-08-01 | $23.50M derived: sum of 3 quarters · filed 2024-02-09 | -$102.70M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-03-31 | -$31.60M 10-Q · filed 2023-05-03 | -$7.90M derived: sum of 2 quarters · filed 2024-02-09 | -$134.10M derived: sum of 3 quarters · filed 2024-02-09 | -$224.90M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2021-12-31 | $23.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | -$102.50M derived: sum of 2 quarters · filed 2024-02-09 | -$193.30M derived: sum of 3 quarters · filed 2024-02-09 | -$130.20M 10-K · filed 2024-02-09 | ||||
| 2021-09-30 | -$126.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$217.00M derived: sum of 2 quarters · filed 2022-11-01 | -$153.90M 10-Q · filed 2022-11-01 | -$301.60M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-06-30 | -$90.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$27.70M 10-Q · filed 2022-08-04 | -$175.40M derived: sum of 3 quarters · filed 2023-02-09 | -$150.20M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-03-31 | $63.10M 10-Q · filed 2022-05-04 | -$84.60M derived: sum of 2 quarters · filed 2023-02-09 | -$59.40M derived: sum of 3 quarters · filed 2023-02-09 | $34.00M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2020-12-31 | -$147.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$122.50M derived: sum of 2 quarters · filed 2023-02-09 | -$29.10M derived: sum of 3 quarters · filed 2023-02-09 | $4.10M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | $25.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $118.60M derived: sum of 2 quarters · filed 2021-11-01 | $151.80M 10-Q · filed 2021-11-01 | -$14.40M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-06-30 | $93.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $126.60M 10-Q · filed 2021-08-03 | -$39.60M derived: sum of 3 quarters · filed 2022-02-11 | -$125.20M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-03-31 | $33.20M 10-Q · filed 2021-05-05 | -$133.00M derived: sum of 2 quarters · filed 2022-02-11 | -$218.60M derived: sum of 3 quarters · filed 2022-02-11 | -$218.90M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2019-12-31 | -$166.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | -$251.80M derived: sum of 2 quarters · filed 2022-02-11 | -$252.10M derived: sum of 3 quarters · filed 2022-02-11 | -$211.10M 10-K · filed 2022-02-11 | -$211.07M 10-K · filed 2020-02-07 | |||
| 2019-09-30 | -$85.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$85.90M derived: sum of 2 quarters · filed 2020-11-09 | -$44.90M 10-Q · filed 2020-11-09 | -$44.91M 10-Q · filed 2019-11-04 | -$151.14M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2019-06-30 | -$300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $40.70M 10-Q · filed 2020-08-03 | $40.73M 10-Q · filed 2019-07-29 | -$65.54M derived: sum of 3 quarters · filed 2021-02-05 | -$110.64M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2019-03-31 | $41.00M 10-Q · filed 2020-05-06 | $40.97M 10-Q · filed 2019-04-29 | -$65.24M derived: sum of 2 quarters · filed 2021-02-05 | -$110.34M derived: sum of 3 quarters · filed 2021-02-05 | -$144.85M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2018-12-31 | -$106.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | -$151.34M derived: sum of 2 quarters · filed 2021-02-05 | -$185.85M derived: sum of 3 quarters · filed 2021-02-05 | -$242.90M 10-K · filed 2021-02-05 | -$242.91M 10-K · filed 2019-02-08 | |||
| 2018-09-30 | -$45.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$79.61M derived: sum of 2 quarters · filed 2019-11-04 | -$136.66M 10-Q · filed 2019-11-04 | -$196.05M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-06-30 | -$34.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | -$91.56M 10-Q · filed 2019-07-29 | -$150.96M derived: sum of 3 quarters · filed 2020-02-07 | -$186.35M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-03-31 | -$57.05M 10-Q · filed 2019-04-29 | -$116.44M derived: sum of 2 quarters · filed 2020-02-07 | -$151.84M derived: sum of 3 quarters · filed 2020-02-07 | |||||
| 2017-12-31 | -$59.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | -$94.79M derived: sum of 2 quarters · filed 2020-02-07 | -$251.25M 10-K · filed 2020-02-07 | |||||
| 2017-09-30 | -$35.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$191.86M 10-Q · filed 2018-11-05 | ||||||
| 2017-06-30 | -$156.47M 10-Q · filed 2018-07-31 | |||||||
| 2016-12-31 | $112.95M 10-K · filed 2019-02-08 | |||||||
| 2013-12-31 | $20.73M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $19.42M derived: sum of 2 quarters · filed 2014-02-11 | $40.42M derived: sum of 3 quarters · filed 2014-02-11 | $5.34M 10-K · filed 2014-02-11 | ||||
| 2013-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $19.69M derived: sum of 2 quarters · filed 2013-10-29 | -$15.39M 10-Q · filed 2013-10-29 | $12.50M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2013-06-30 | $20.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | -$14.08M 10-Q · filed 2013-07-26 | $13.80M derived: sum of 3 quarters · filed 2014-02-11 | $24.46M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2013-03-31 | -$35.08M 10-Q · filed 2013-05-02 | -$7.19M derived: sum of 2 quarters · filed 2014-02-11 | $3.46M derived: sum of 3 quarters · filed 2014-02-11 | -$24.62M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-12-31 | $27.89M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $38.54M derived: sum of 2 quarters · filed 2014-02-11 | $10.46M derived: sum of 3 quarters · filed 2014-02-11 | -$34.76M 10-K · filed 2014-02-11 | ||||
| 2012-09-30 | $10.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | -$17.43M derived: sum of 2 quarters · filed 2013-10-29 | -$62.65M 10-Q · filed 2013-10-29 | -$63.10M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-06-30 | -$28.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | -$73.30M 10-Q · filed 2013-07-26 | -$73.75M derived: sum of 3 quarters · filed 2014-02-11 | -$55.89M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | -$45.22M 10-Q · filed 2013-05-02 | -$45.67M derived: sum of 2 quarters · filed 2014-02-11 | -$27.81M derived: sum of 3 quarters · filed 2014-02-11 | -$27.61M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2011-12-31 | -$451.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $17.41M derived: sum of 2 quarters · filed 2014-02-11 | $17.60M derived: sum of 3 quarters · filed 2014-02-11 | -$3.53M 10-K · filed 2014-02-11 | -$3.55M 10-K · filed 2012-02-09 | |||
| 2011-09-30 | $17.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | $18.05M derived: sum of 2 quarters · filed 2012-10-31 | -$3.08M 10-Q · filed 2012-10-31 | -$21.93M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2011-06-30 | $193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-31 | -$20.94M 10-Q · filed 2012-07-31 | -$39.79M derived: sum of 3 quarters · filed 2013-02-08 | -$58.74M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2011-03-31 | -$21.14M 10-Q · filed 2012-05-02 | -$39.98M derived: sum of 2 quarters · filed 2013-02-08 | -$58.94M derived: sum of 3 quarters · filed 2013-02-08 | |||||
| 2010-12-31 | -$18.85M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | -$37.80M derived: sum of 2 quarters · filed 2013-02-08 | -$54.70M 10-K · filed 2013-02-08 | |||||
| 2010-09-30 | -$18.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | -$35.85M 10-Q · filed 2011-10-31 | ||||||
| 2010-06-30 | -$16.90M 10-Q · filed 2011-07-29 | |||||||
| 2009-12-31 | $12.06M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |